

如何快速掌控某药物相关的临床试验信息？

Thomson Pharma 为您提供独特的药物研发状态竞争性情报，特别整合临床试验内容，快速展现您关心的药物或公司的临床试验全景。掌控所有治疗领域的临床试验最新内容，有效提高您设计和分析研发阶段的能力！

临床试验内容可以帮助您解决如下问题：

- 在我关心的治疗领域，还有哪些药物正在进行有效性研究？
- 与当前临床试验全景相比较，我是如何领先（或落后）他人的？
- 对于我即将进行的临床试验，世界各地有哪些同类试验研究？其计划何时开始或结束？
- 若想获得注册批准和市场成功，我的临床试验结果应该达到或超过怎样的预期？

例：检索吡格列酮 Pioglitazone 的临床试验信息

方法1：使用表格检索 **Form Search – Clinical Trial Protocol**, 或 **Form Search – Clinical Trial Outcomes**.

例：**Form Search – Clinical Trial Protocol**

Home > Protocols Search

Form search - Clinical trial protocols

Intervention name <Pioglitazone>
Study Sponsors <Takeda Pharmaceutical Co Ltd>

Condition(s) studied

Search for interventions by: Name(s) Type

Intervention name(s)
pioglitazone

Primary Comparator Active control Any

Intervention name(s)

Primary Comparator Active control Any

Intervention type

Study phase

Study sponsors
Takeda Pharmaceutical Co Ltd

Sponsored by:
 Academia Government Industry

Search for age by:
 Age groups
 Min and max age in years

Age groups:
Min: Max:

Eligibility restricted to ethnic group:

Recruiting status

Study countries

Enroll
Expect

点击树状图标，查看标准词表索引

优势 **Form Search – Clinical Trials Protocol**:

- 1) 可以设置详细检索条件进行检索，例如研究设计和临床试验阶段等
- 2) 可以使用标准词表索引

检索结果显示临床试验的名称，点击蓝色超链接打开临床试验设计方案报告<**Protocol report**>

PR An efficacy study of pioglitazone in patients...

链接至相关药物报告和公司报告

临床试验设计方案报告和临床试验结果报告的数据来源:

- 1) 新闻发布, 学术会议, ClinicalTrials.gov, 主办方或专利局网站, 新闻消息, 投资或分析会议, 直接与公司的沟通联系
- 2) 在 Thomson Pharma 数据库中出现的早于 ClinicalTrials.gov 的临床试验信息主要来源于文献

方法 II: 打开吡格列酮药物报告进行查看 <Clinical Trials, Overview tab 或 Development Status>.

1) 点击 <Clinical trials>.

按照主办方分别显示临床试验信息
- 显示临床试验信息的主办方, 不显示合作方

点击查看<Protocol report>

提供临床试验结果报告 Outcome report, 点击 <Yes>进行查看

- 1) Clinical Trials 标签显示所有与本药物相关的 Protocol Reports
- 2) 点击超链接可以查看所有的 Protocol reports

2) 点击 <Overview>

OVERVIEW	DEVELOPMENT STATUS	LITERATURE EVALUATION	CHEMISTRY	DRUGDEX EVALUATION	STRATEGIC PROFILE	PATENTS	CLINICAL TRIALS	BIBLIOGRAPHY
----------	--------------------	-----------------------	-----------	--------------------	-------------------	---------	-----------------	--------------

OVERVIEW ⓘ

Overview 标签提供重大临床试验信息总结

Multiple sclerosis

In October 2003, a randomized, double-blind, parallel, phase I, pilot trial (NCT00242177) was initiated in patients (n = 30) with relapsing remitting multiple sclerosis in the US. Patients were randomized to receive pioglitazone (30 mg/day) or placebo for up to 18 months. Primary endpoints were MRI, blood test, Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC) results at each visit. This study was completed in October 2005 [[1023126](#)].

Miscellaneous studies

In November 2004, data from a trial investigating pioglitazone in the improvement of left ventricular diastolic function in patients with essential hypertension were presented by the National Cardiovascular Center at the AHA meeting in New Orleans, LA. The trial enrolled 30 essential hypertension patients with glucose intolerance to receive 15 to 30 mg/day pioglitazone for 6 months. Administration of pioglitazone increased the peak velocity ratio of early diastolic filling to arterial filling, decreased E-wave deceleration time and did not alter left ventricular mass index. These improvements were directly correlated with a decrease in steady-state plasma glucose [[570772](#)], [[570792](#)].

PRECLINICAL STUDIES

Non-insulin dependent diabetes

In March 1999, it was reported at the Third International Symposium for Insulin Resistance that when pioglitazone was given to

3) 点击 <Development Status>

OVERVIEW	DEVELOPMENT STATUS	LITERATURE EVALUATION	CHEMISTRY	DRUGDEX EVALUATION	STRATEGIC PROFILE	PATENTS	CLINICAL TRIALS	BIBLIOGRAPHY
----------	--------------------	-----------------------	-----------	--------------------	-------------------	---------	-----------------	--------------

DEVELOPMENT STATUS ⓘ

Detailed Status for [Eli Lilly & Co](#)

Therapy Area	Country	Status	Reference	Date
Non-insulin dependent diabetes	Canada	Discontinued	1035945	21-AUG-2009
Non-insulin dependent diabetes	US	Launched	338000	26-AUG-1999
Non-insulin dependent diabetes	Western Europe	Launched	338000	25-AUG-1999

点击 <Developmental Status> 查看不同国家的不同公司的临床试验研发阶段